1. Ahmadikia K, Hashemi SJ, Khodavaisy S, Getso MI, Alijani N, Badali H, et al. The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis. Mycoses. 2021;64:798-808.

https://doi.org/10.1111/myc.13256

PMid:33590551 PMCid:PMC8013756

2. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-53.

https://doi.org/10.1086/432579

PMid:16080086 

3. Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021;20:418-25.

https://doi.org/10.1007/s12663-021-01532-1

PMid:33716414 PMCid:PMC7936599

4. Goel A, Kini U, Shetty S. Role of histopathology as an aid to prognosis in rhino-orbito-cerebral zygomycosis. Indian J Pathol Microbiol. 2010;53:253.

https://doi.org/10.4103/0377-4929.64342

PMid:20551527 

5. Sridhar CB, Kini U, Subhash K. Comparative cytological study of lymph node tuberculosis in HIV‐infected individuals and in patients with diabetes in a developing country. Diagn Cytopathol. 2002;26:75-80.

https://doi.org/10.1002/dc.10059

PMid:11813322 

6. Shah K, Dave V, Bradoo R, Shinde C, Prathibha M. Orbital exenteration in rhino-orbito-cerebral mucormycosis: a prospective analytical study with scoring system. Indian J Otolaryngol Head Neck Surg. 2019;71:259-65.

https://doi.org/10.1007/s12070-018-1293-8

PMid:31275841 PMCid:PMC6582081

7. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021;135:442-7.

https://doi.org/10.1017/S0022215121000992

PMid:33827722 PMCid:PMC8060545

8. Raut A, Huy NT. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?. Lancet Respir Med. 2021;9:e77.

https://doi.org/10.1016/S2213-2600(21)00265-4

PMid:34090607 

9. Ramaswami A, Sahu AK, Kumar A, Suresh S, Nair A, Gupta D, et al. COVID-19-associated mucormycosis presenting to the Emergency Department-an observational study of 70 patients. QJM. 2021;114:464-70.

https://doi.org/10.1093/qjmed/hcab190

PMid:34254132 PMCid:PMC8420631

10. Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26:944-e9.

https://doi.org/10.1016/j.cmi.2019.11.021

PMid:31811914 

11. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.

https://doi.org/10.3389/fimmu.2020.01446

PMid:32612617 PMCid:PMC7308649

12. Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556-69.

https://doi.org/10.1128/CMR.18.3.556-569.2005

PMid:16020690 PMCid:PMC1195964

13. Sravani T, Uppin SG, Uppin MS, Sundaram C. Rhinocerebral mucormycosis: Pathology revisited with emphasis on perineural spread. Neurol India. 2014;62:383.

https://doi.org/10.4103/0028-3886.141252

PMid:25237943